Stopfer P, Giessmann T, Hohl K, Sharma A, Ishiguro N, Taub M E, Zimdahl-Gelling H, Gansser D, Wein M, Ebner T, Müller F
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.
Nippon Boehringer Ingelheim, Kobe, Japan.
Clin Pharmacol Ther. 2016 Sep;100(3):259-67. doi: 10.1002/cpt.406. Epub 2016 Jul 29.
This article reports the clinical investigation of a probe drug cocktail containing substrates of key drug transporters. Single oral doses of 0.25 mg digoxin (P-gp), 5 mg furosemide (OAT1 and OAT3), 500 mg metformin (OCT2, MATE1, and MATE2-K), and 10 mg rosuvastatin (OATP1B1, OATP1B3, and BCRP) were administered separately or as a cocktail in a randomized six-period crossover trial in 24 healthy male volunteers. As a cocktail, relative bioavailabilities of digoxin and metformin and furosemide AUC0-tz were similar to separate dosing. However, when administered as a cocktail the Cmax of furosemide was 19.1% lower and the Cmax and AUC0-tz of rosuvastatin were 38.6% and 43.4% higher, respectively. In addition, the effects of increased doses of metformin or furosemide on the cocktail were investigated in 11 and 12 subjects, respectively. The cocktail explored in this trial has the potential to be used for the in vivo screening of transporter-mediated drug-drug interactions. © 2016 American Society for Clinical Pharmacology and Therapeutics.
本文报道了一种含有关键药物转运体底物的探针药物混合物的临床研究。在一项随机六周期交叉试验中,对24名健康男性志愿者分别单独给予0.25mg地高辛(P-糖蛋白)、5mg呋塞米(OAT1和OAT3)、500mg二甲双胍(OCT2、MATE1和MATE2-K)以及10mg瑞舒伐他汀(OATP1B1、OATP1B3和BCRP),或将其作为混合物给药。作为混合物给药时,地高辛、二甲双胍以及呋塞米AUC0-tz的相对生物利用度与单独给药相似。然而,作为混合物给药时,呋塞米的Cmax降低了19.1%,瑞舒伐他汀的Cmax和AUC0-tz分别升高了38.6%和43.4%。此外,分别在11名和12名受试者中研究了增加二甲双胍或呋塞米剂量对混合物的影响。本试验中探索的混合物有潜力用于转运体介导的药物-药物相互作用的体内筛选。©2016美国临床药理学与治疗学协会。